Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

KEYTRUDA, in patients with advanced solid tumors. KVA12123 cleared all six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

CNBC's Becky Quick reports on the company's quarterly earnings results. Kamala Harris Could Break 32-Year Record in Texas, Survey Suggests The IRS just made a ruling on 401(k) company matches that ...

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding ...